Lupin Receives Approval From U.S. FDA For Pirfenidone Capsules

Lupin Receives Approval From U.S. FDA For Pirfenidone Capsules

This product will be manufactured at Lupin’s Pithampur facility in India.

FPJ Web DeskUpdated: Tuesday, August 29, 2023, 01:06 PM IST
article-image
Lupin Receives Approval From U.S. FDA For Pirfenidone Capsules | Image: Wikipedia (Representative)

Global pharma major Lupin Limited (Lupin) on Tuesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pirfenidone Capsules, 267 mg, to market a generic equivalent of Esbriet® Capsules, 267 mg of Hoffmann La Roche Inc., the company announced through an exchange filing.

This product will be manufactured at Lupin’s Pithampur facility in India.

Pirfenidone Capsules (RLD Esbriet) had estimated annual sales of USD 95 million in the U.S. (IQVIA MAT June 2023).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9 percent of its revenue in research and development in FY23.

Lupin shares

The shares of Lupin on Tuesday at 1:02 pm IST were at Rs 1,104.50, down by 0.32 percent.

RECENT STORIES

Integral To Your Premium Experience: The 2024 Acura Integra

Integral To Your Premium Experience: The 2024 Acura Integra

Elon Musk Projects SpaceX To Deliver Over 90% Of Earth's Payloads To Orbit By Year-End

Elon Musk Projects SpaceX To Deliver Over 90% Of Earth's Payloads To Orbit By Year-End

Kerala's Revenue Soars To ₹77,000 Crore, Easing Financial Strain From Centre

Kerala's Revenue Soars To ₹77,000 Crore, Easing Financial Strain From Centre

RVNL Zooms Over 13% Amidst ₹148 Crore Order From South Eastern Railway

RVNL Zooms Over 13% Amidst ₹148 Crore Order From South Eastern Railway

'Yeh Sab Doglapan Hai': Netizens Troll Ashneer Grover Over 'Comedy Roast' Fiasco

'Yeh Sab Doglapan Hai': Netizens Troll Ashneer Grover Over 'Comedy Roast' Fiasco